236 related articles for article (PubMed ID: 20946699)
1. The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT(2C) receptors.
Millan MJ; Marin P; Kamal M; Jockers R; Chanrion B; Labasque M; Bockaert J; Mannoury la Cour C
Int J Neuropsychopharmacol; 2011 Jul; 14(6):768-83. PubMed ID: 20946699
[TBL] [Abstract][Full Text] [Related]
2. Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction.
Chanrion B; Mannoury la Cour C; Gavarini S; Seimandi M; Vincent L; Pujol JF; Bockaert J; Marin P; Millan MJ
Mol Pharmacol; 2008 Mar; 73(3):748-57. PubMed ID: 18083778
[TBL] [Abstract][Full Text] [Related]
3. Constitutive activity of serotonin 2C receptors at G protein-independent signaling: modulation by RNA editing and antidepressants.
Labasque M; Meffre J; Carrat G; Becamel C; Bockaert J; Marin P
Mol Pharmacol; 2010 Nov; 78(5):818-26. PubMed ID: 20699324
[TBL] [Abstract][Full Text] [Related]
4. Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: a comparison to melatonin and to the 5-HT(2c) antagonist, S32006.
Norman TR; Cranston I; Irons JA; Gabriel C; Dekeyne A; Millan MJ; Mocaër E
Eur J Pharmacol; 2012 Jan; 674(1):27-32. PubMed ID: 22040921
[TBL] [Abstract][Full Text] [Related]
5. S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models.
Dekeyne A; Mannoury la Cour C; Gobert A; Brocco M; Lejeune F; Serres F; Sharp T; Daszuta A; Soumier A; Papp M; Rivet JM; Flik G; Cremers TI; Muller O; Lavielle G; Millan MJ
Psychopharmacology (Berl); 2008 Sep; 199(4):549-68. PubMed ID: 18523738
[TBL] [Abstract][Full Text] [Related]
6. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.
Millan MJ; Mannoury la Cour C; Chanrion B; Dupuis DS; Di Cara B; Audinot V; Cussac D; Newman-Tancredi A; Kamal M; Boutin JA; Jockers R; Marin P; Bockaert J; Muller O; Dekeyne A; Lavielle G
J Pharmacol Exp Ther; 2012 Mar; 340(3):750-64. PubMed ID: 22178752
[TBL] [Abstract][Full Text] [Related]
7. Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking.
Cussac D; Newman-Tancredi A; Duqueyroix D; Pasteau V; Millan MJ
Mol Pharmacol; 2002 Sep; 62(3):578-89. PubMed ID: 12181434
[TBL] [Abstract][Full Text] [Related]
8. Agomelatine(S 20098) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats.
Chagraoui A; Protais P; Filloux T; Mocaër E
Psychopharmacology (Berl); 2003 Oct; 170(1):17-22. PubMed ID: 12904965
[TBL] [Abstract][Full Text] [Related]
9. Agomelatine affects rat suprachiasmatic nucleus neurons via melatonin and serotonin receptors.
Yang J; Jin HJ; Mocaër E; Seguin L; Zhao H; Rusak B
Life Sci; 2016 Jun; 155():147-54. PubMed ID: 27269050
[TBL] [Abstract][Full Text] [Related]
10. Techniques for studying inverse agonist activity of antidepressants at recombinant nonedited 5-HT(₂C-INI) receptor and native neuronal 5-HT(₂C) receptors.
Seimandi M; Bockaert J; Marin P
Methods Enzymol; 2010; 485():61-79. PubMed ID: 21050911
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus.
Soumier A; Banasr M; Lortet S; Masmejean F; Bernard N; Kerkerian-Le-Goff L; Gabriel C; Millan MJ; Mocaer E; Daszuta A
Neuropsychopharmacology; 2009 Oct; 34(11):2390-403. PubMed ID: 19571795
[TBL] [Abstract][Full Text] [Related]
12. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade.
Millan MJ; Brocco M; Gobert A; Dekeyne A
Psychopharmacology (Berl); 2005 Feb; 177(4):448-58. PubMed ID: 15289999
[TBL] [Abstract][Full Text] [Related]
13. Convergence of melatonin and serotonin (5-HT) signaling at MT2/5-HT2C receptor heteromers.
Kamal M; Gbahou F; Guillaume JL; Daulat AM; Benleulmi-Chaachoua A; Luka M; Chen P; Kalbasi Anaraki D; Baroncini M; Mannoury la Cour C; Millan MJ; Prevot V; Delagrange P; Jockers R
J Biol Chem; 2015 May; 290(18):11537-46. PubMed ID: 25770211
[TBL] [Abstract][Full Text] [Related]
14. Serotonin 5-HT(2C) receptor homodimerization is not regulated by agonist or inverse agonist treatment.
Herrick-Davis K; Grinde E; Weaver BA
Eur J Pharmacol; 2007 Jul; 568(1-3):45-53. PubMed ID: 17507008
[TBL] [Abstract][Full Text] [Related]
15. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways.
Millan MJ; Gobert A; Lejeune F; Dekeyne A; Newman-Tancredi A; Pasteau V; Rivet JM; Cussac D
J Pharmacol Exp Ther; 2003 Sep; 306(3):954-64. PubMed ID: 12750432
[TBL] [Abstract][Full Text] [Related]
16. Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors.
Racagni G; Riva MA; Molteni R; Musazzi L; Calabrese F; Popoli M; Tardito D
World J Biol Psychiatry; 2011 Dec; 12(8):574-87. PubMed ID: 21999473
[TBL] [Abstract][Full Text] [Related]
17. Agomelatine in the tree shrew model of depression: effects on stress-induced nocturnal hyperthermia and hormonal status.
Schmelting B; Corbach-Söhle S; Kohlhause S; Schlumbohm C; Flügge G; Fuchs E
Eur Neuropsychopharmacol; 2014 Mar; 24(3):437-47. PubMed ID: 23978391
[TBL] [Abstract][Full Text] [Related]
18. Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture.
Descamps A; Rousset C; Millan MJ; Spedding M; Delagrange P; Cespuglio R
Psychopharmacology (Berl); 2009 Jul; 205(1):93-106. PubMed ID: 19370342
[TBL] [Abstract][Full Text] [Related]
19. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.
Newman-Tancredi A; Cussac D; Quentric Y; Touzard M; Verrièle L; Carpentier N; Millan MJ
J Pharmacol Exp Ther; 2002 Nov; 303(2):815-22. PubMed ID: 12388668
[TBL] [Abstract][Full Text] [Related]
20. Blockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways.
Tardito D; Milanese M; Bonifacino T; Musazzi L; Grilli M; Mallei A; Mocaer E; Gabriel-Gracia C; Racagni G; Popoli M; Bonanno G
BMC Neurosci; 2010 Jun; 11():68. PubMed ID: 20525261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
